Fig. 7
From: The potential roles of gossypol as anticancer agent: advances and future directions
Inhibition of angiogenesis in tumor cells by gossypol.  It exerts this therapeutic effect by downregulating the expression of vascular endothelial growth factor (VEGF), a critical protein that stimulates the formation of new blood vessels (angiogenesis) within tumor tissues. The suppression of VEGF leads to a decrease in new blood vessel formation, effectively starving the tumor of the necessary nutrients and oxygen needed for growth. Additionally, gossypol interferes with the MDM2 protein within the nucleus. MDM2 is known to negatively regulate the tumor suppressor p53, and by inhibiting MDM2, gossypol may contribute to the reactivation of p53's tumor-suppressive functions. Through these mechanisms, gossypol effectively inhibits tumor angiogenesis, contributing to its anticancer effects. VEGF Vascular Endothelial Growth Factor, MDM2 Mouse Double Minute 2 Homolog